Filing Flows › Champions Oncology (CSBR) › Q3 FY25
Champions Oncology (CSBR) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Mar 17, 2025
Champions Oncology (CSBR) reported revenue of $17.0M for the third quarter fiscal 2025 (Q3 FY25), +42% from a year earlier and +26% from the quarter before. Operating margin was 26.4%, net earnings $4.5M (26.4% of revenue).
Champions Oncology, Q3 FY25: revenue $17.0M (+42% year over year), operating margin 26.4%, net earnings $4.5M, operating cash flow $490K. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.0M | +26% | +42% |
| Operating profit | $4.5M | +515% | — |
| Net earnings | $4.5M | +517% | — |
| Operating cash flow | $490K | — | — |
| Free cash flow | $448K | — | — |
What changed
Revenue was $17.0M in Q3 FY25, up 42% year over year and up 26% from the previous quarter. Pharmacology services was the largest line at 68% of revenue. Pharmacology services added $486K year over year (up 4%), 10% of the total change.
Operating profit was $4.5M, a 26.4% margin (up 47.8 points year over year). Total costs fell 14% while revenue rose 42%. Net earnings were $4.5M. The effective tax rate was 0.5%.
Operating cash flow was $490K, 11% of net earnings. Non-cash charges added back $398K of depreciation and amortization and $256K of share-based compensation. Working capital and other items used $4.7M. Capital expenditures of $42K left free cash flow of $448K.
Questions
What was Champions Oncology's revenue in the third quarter fiscal 2025?
Champions Oncology (CSBR) reported revenue of $17.0M for the third quarter fiscal 2025 (Q3 FY25), +42% from a year earlier and +26% from the quarter before.
Was Champions Oncology profitable in the third quarter fiscal 2025?
Operating profit was $4.5M (26.4% of revenue) and net earnings $4.5M.
Source: Champions Oncology 10-Q on SEC EDGAR.